Literature DB >> 25833952

Cysteine Cathepsins Activate ELR Chemokines and Inactivate Non-ELR Chemokines.

Urska Repnik1, Amanda E Starr2, Christopher M Overall3, Boris Turk4.   

Abstract

Cysteine cathepsins are primarily lysosomal proteases involved in general protein turnover, but they also have specific proteolytic functions in antigen presentation and bone remodeling. Cathepsins are most stable at acidic pH, although growing evidence indicates that they have physiologically relevant activity also at neutral pH. Post-translational proteolytic processing of mature chemokines is a key, yet underappreciated, level of chemokine regulation. Although the role of selected serine proteases and matrix metalloproteases in chemokine processing has long been known, little has been reported about the role of cysteine cathepsins. Here we evaluated cleavage of CXC ELR (CXCL1, -2, -3, -5, and -8) and non-ELR (CXCL9-12) chemokines by cysteine cathepsins B, K, L, and S at neutral pH by high resolution Tris-Tricine SDS-PAGE and matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Whereas cathepsin B cleaved chemokines especially in the C-terminal region, cathepsins K, L, and S cleaved chemokines at the N terminus with glycosaminoglycans modulating cathepsin processing of chemokines. The functional consequences of the cleavages were determined by Ca(2+) mobilization and chemotaxis assays. We show that cysteine cathepsins inactivate and in some cases degrade non-ELR CXC chemokines CXCL9-12. In contrast, cathepsins specifically process ELR CXC chemokines CXCL1, -2, -3, -5, and -8 N-terminally to the ELR motif, thereby generating agonist forms. This study suggests that cysteine cathepsins regulate chemokine activity and thereby leukocyte recruitment during protective or pathological inflammation.
© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  CXC chemokine; chemokine; chemokine processing; cysteine cathepsin; glycosaminoglycan; inflammation; mass spectrometry (MS); proteolysis

Mesh:

Substances:

Year:  2015        PMID: 25833952      PMCID: PMC4447957          DOI: 10.1074/jbc.M115.638395

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  69 in total

1.  Autocatalytic processing of recombinant human procathepsin B is a bimolecular process.

Authors:  J Rozman; J Stojan; R Kuhelj; V Turk; B Turk
Journal:  FEBS Lett       Date:  1999-10-15       Impact factor: 4.124

Review 2.  Structural basis of chemokine receptor function--a model for binding affinity and ligand selectivity.

Authors:  Lavanya Rajagopalan; Krishna Rajarathnam
Journal:  Biosci Rep       Date:  2006-10       Impact factor: 3.840

Review 3.  In search of partners: linking extracellular proteases to substrates.

Authors:  Christopher M Overall; Carl P Blobel
Journal:  Nat Rev Mol Cell Biol       Date:  2007-02-14       Impact factor: 94.444

Review 4.  Emerging roles of cysteine cathepsins in disease and their potential as drug targets.

Authors:  Olga Vasiljeva; Thomas Reinheckel; Christoph Peters; Dusan Turk; Vito Turk; Boris Turk
Journal:  Curr Pharm Des       Date:  2007       Impact factor: 3.116

5.  Proteomics discovery of metalloproteinase substrates in the cellular context by iTRAQ labeling reveals a diverse MMP-2 substrate degradome.

Authors:  Richard A Dean; Christopher M Overall
Journal:  Mol Cell Proteomics       Date:  2007-01-01       Impact factor: 5.911

6.  Isolation of the CXC chemokines ENA-78, GRO alpha and GRO gamma from tumor cells and leukocytes reveals NH2-terminal heterogeneity. Functional comparison of different natural isoforms.

Authors:  A Wuyts; C Govaerts; S Struyf; J P Lenaerts; W Put; R Conings; P Proost; J Van Damme
Journal:  Eur J Biochem       Date:  1999-03

Review 7.  Cysteine cathepsins and the cutting edge of cancer invasion.

Authors:  Vasilena Gocheva; Johanna A Joyce
Journal:  Cell Cycle       Date:  2007-01-06       Impact factor: 4.534

8.  Cysteine proteinase activity regulation. A possible role of heparin and heparin-like glycosaminoglycans.

Authors:  P C Almeida; I L Nantes; C C Rizzi; W A Júdice; J R Chagas; L Juliano; H B Nader; I L Tersariol
Journal:  J Biol Chem       Date:  1999-10-22       Impact factor: 5.157

Review 9.  The biological relevance of chemokine-proteoglycan interactions.

Authors:  A E I Proudfoot
Journal:  Biochem Soc Trans       Date:  2006-06       Impact factor: 5.407

10.  LPS responsiveness and neutrophil chemotaxis in vivo require PMN MMP-8 activity.

Authors:  Angus M Tester; Jennifer H Cox; Andrea R Connor; Amanda E Starr; Richard A Dean; Xose S Puente; Carlos López-Otín; Christopher M Overall
Journal:  PLoS One       Date:  2007-03-21       Impact factor: 3.240

View more
  22 in total

Review 1.  Engineered nanomaterial-induced lysosomal membrane permeabilization and anti-cathepsin agents.

Authors:  Melisa Bunderson-Schelvan; Andrij Holian; Raymond F Hamilton
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2017       Impact factor: 6.393

2.  Proteomic Identification of Cysteine Cathepsin Substrates Shed from the Surface of Cancer Cells.

Authors:  Barbara Sobotič; Matej Vizovišek; Robert Vidmar; Petra Van Damme; Vasilena Gocheva; Johanna A Joyce; Kris Gevaert; Vito Turk; Boris Turk; Marko Fonović
Journal:  Mol Cell Proteomics       Date:  2015-06-16       Impact factor: 5.911

3.  Septin oligomerization regulates persistent expression of ErbB2/HER2 in gastric cancer cells.

Authors:  Elizabeth A Marcus; Elmira Tokhtaeva; Shahlo Turdikulova; Joseph Capri; Julian P Whitelegge; David R Scott; George Sachs; Fedor Berditchevski; Olga Vagin
Journal:  Biochem J       Date:  2016-04-05       Impact factor: 3.857

Review 4.  Targeting Proteases in Cystic Fibrosis Lung Disease. Paradigms, Progress, and Potential.

Authors:  Michael C McKelvey; Sinéad Weldon; Daniel F McAuley; Marcus A Mall; Clifford C Taggart
Journal:  Am J Respir Crit Care Med       Date:  2020-01-15       Impact factor: 21.405

5.  CCL2 is transcriptionally controlled by the lysosomal protease cathepsin S in a CD74-dependent manner.

Authors:  Richard D A Wilkinson; Sinead M Magorrian; Rich Williams; Andrew Young; Donna M Small; Christopher J Scott; Roberta E Burden
Journal:  Oncotarget       Date:  2015-10-06

Review 6.  Regulation of Chemokine Activity - A Focus on the Role of Dipeptidyl Peptidase IV/CD26.

Authors:  Mieke Metzemaekers; Jo Van Damme; Anneleen Mortier; Paul Proost
Journal:  Front Immunol       Date:  2016-11-11       Impact factor: 7.561

7.  Induction of cathepsin B by the CXCR3 chemokines CXCL9 and CXCL10 in human breast cancer cells.

Authors:  Holger Bronger; Anne Karge; Tobias Dreyer; Daniela Zech; Sara Kraeft; Stefanie Avril; Marion Kiechle; Manfred Schmitt
Journal:  Oncol Lett       Date:  2017-04-05       Impact factor: 2.967

8.  A bioavailable cathepsin S nitrile inhibitor abrogates tumor development.

Authors:  Richard D A Wilkinson; Andrew Young; Roberta E Burden; Rich Williams; Christopher J Scott
Journal:  Mol Cancer       Date:  2016-04-21       Impact factor: 27.401

9.  Cathepsin B-Deficient Mice Resolve Leishmania major Inflammation Faster in a T Cell-Dependent Manner.

Authors:  Orhan Rasid; Véronique Mériaux; Erin M Khan; Chloé Borde; Ioana S Ciulean; Catherine Fitting; Bénédicte Manoury; Jean-Marc Cavaillon; Noëlle Doyen
Journal:  PLoS Negl Trop Dis       Date:  2016-05-16

Review 10.  Cathepsin S: investigating an old player in lung disease pathogenesis, comorbidities, and potential therapeutics.

Authors:  Ryan Brown; Sridesh Nath; Alnardo Lora; Ghassan Samaha; Ziyad Elgamal; Ryan Kaiser; Clifford Taggart; Sinéad Weldon; Patrick Geraghty
Journal:  Respir Res       Date:  2020-05-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.